Skip to main content
. 2014 Feb 22;35(9):1951–1961. doi: 10.1093/carcin/bgu049

Fig. 4.

Fig. 4.

AKT inhibition combined with CQ treatment reduces cell viability. (A–C) Triplicate wells of 96-well plates were seeded, allowed to attach overnight, treated for 72h with Akti-1/2 (EC50) and CQ (50 μM), and viability assessed by alamarBlue. (A) Viability readings normalized to vehicle control (DMSO) for eight individual EOC samples. Bars: mean ± SD. (B) Normalized viability data pooled from all EOC samples (n = 8) and (C) iOvCa147-E2 cells (n = 3). Bars: mean ± SEM. Different letters denote statistically significant differences based on one-way analysis of variance with Tukey’s test of multiple comparisons (P ≤ 0.001). (D and E) Triplicate wells were treated with a range of CQ doses (0, 2.5, 5.0, 10, 25, 50, 75, 100, 150, 250 μM) combined with either DMSO or Akti-1/2 (EC50) and viability assessed at 72h. (D) Non-linear curve-fit analysis and EC50 comparisons performed for iOvCa147-E2 cells (P < 0.001). (E) CQ EC50 comparisons for iOvCa147-E2 cells and 11 independent EOC samples. Bars: mean ± 95% confidence interval.